We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Groupe Crit | EU:CEN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.27% | 74.60 | 74.60 | 75.40 | 75.00 | 74.60 | 74.80 | 356 | 16:40:00 |
RNS Number:3209U CeNeS Pharmaceuticals PLC 16 January 2004 CENES PHARMACEUTICALS PLC ("CeNeS" or "the Company") Notice of Extraordinary General Meeting The directors of CeNeS ("Directors" or "the Board") hereby gives notice that an Extraordinary General Meeting ("EGM") of the Company will be held at the offices of Weil, Gotshal & Manges, One South Place, London EC2M 2WG on 9 February 2004 at 11 a.m. A circular has been sent to shareholders giving full details of the resolutions to be considered at the EGM. The background to the convening of the EGM is set out below. On 21 November 2003, the Company entered into a share exchange agreement with the shareholders of TheraSci Limited ("TheraSci") pursuant to which the Company acquired the entire issued share capital of TheraSci for a total consideration of up to #3,700,000 to be satisfied by the allotment of up to 45,726,209 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"). On 21 November 2003 37,526,931 Ordinary Shares were allotted to the shareholders of TheraSci. The second tranche of 4,576,720 Ordinary Shares is due to be allotted to the shareholders of TheraSci (other than GlaxoSmithKline ("GSK")) as soon as practicable after 21 November 2003 but, in any event, no later than 30 June 2004. In addition, on 21 November 2003, under the terms of an asset purchase agreement with TheraSci, GSK assigned all rights to their programme developing novel short-acting sedatives to TheraSci. Under the terms of this agreement, and subject to the achievement of a particular milestone, the Company is due to allot a further 3,622,558 Ordinary Shares to GSK. Accordingly, an ordinary resolution will be proposed at the EGM which will, inter alia, permit the Company to allot Ordinary Shares in relation to the second tranche of TheraSci deferred consideration shares and the possible milestone payment to GSK. The Company is also taking the opportunity at the EGM to table a special resolution which will enable the Directors of the Company to allot Ordinary Shares, for cash, up to an aggregate value of #250,482.30 representing 10 per cent. of the Ordinary Shares in issue at 13 January 2004. In addition, in accordance with the Combined Code's Code of Best Practise, Dr. Peter Johnson and Alan Smith, who were appointed to the Board on 16 October 2003 and 8 January 2004 respectively, are standing for election by the shareholders at the first opportunity after their appointment. Further information Neil Clark, CeNeS Pharmaceuticals plc 01223 266 466 16 January 2004 This information is provided by RNS The company news service from the London Stock Exchange END NOESFIFFMSLSELF
1 Year Groupe Crit Chart |
1 Month Groupe Crit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions